Volume 11, Number 1—January 2005
SARS Clinical Features, United States, 2003
|Abnormal chest radiograph||8 (100)|
|Bilateral infiltrates||7 (88)|
|Prolonged progression of infiltrates‡||6 (75)|
|Pleural effusions||3 (38)|
|Acute respiratory distress syndrome||1 (13)|
|Hematocrit <36%||2 (25)|
|Leukocyte count <4,000 cells/mm3||2 (25)|
|Absolute lymphocyte count <1,500 cells/mm3||7 (88)|
|Platelets <150,000/mm3||2 (25)|
|Clinical course and outcomes|
|Admitted to intensive care unit||2 (25)|
|Received supplemental oxygen||6 (75)|
|Required mechanical ventilation||1 (13)|
*Features present at any time during course of illness.
†SARS-CoV, severe acute respiratory syndrome–associated coronavirus.
‡Radiographic worsening of infiltrates >7 days after onset of symptoms.
1Dr. Srikantiah is currently a fellow in the Division of Infectious Diseases at the University of California San Francisco.
2Dr. Lingappa is an assistant professor in the Department of Medicine at the University of Washington.
3The CDC SARS Clinical Investigation Team included Akinyi Adija, Bernadette Albanese, Cindy Allard, Felicia Alvarez, Fermin Arguello, Gregory Armstrong, Christine Barton, Geoff Beckett, William Bellini, Megan Davies, Paul Drummond, Dean Erdman, Leigh Farrington, Dara Friedman, Ken Gershman, Jayne Griffith, Kevin Griffith, Heath Harmon, Rita Helfand, Jo Hoffman, Gregory Huhn, Daniel Jernigan, Geraldine Johnson, Paul Kitsutani, Thomas Ksiazek, Ashley LaMonte, Bhrett Lash, Kathryn Lofy, Ruth Lynfield, Joseph Malone, Bela Matyas, Clifford McDonald, Marty Monroe, Steven Monroe, Pat Mshar, Maureen Murphy, Michelle Packard, Neil Pascoe, Michael Phillips, James Rankin, Chesley Richards, Corey Robertson, Peggy Robinson-Dixon, Marc Romney, Maria Pia Sanchez, David Shay, Chad Smelser, David Stephens, Shelley Stonecipher, Tina Tan, Sharon Thompson, J. Todd Weber, and Cindy Weinbaum.
- Page created: April 14, 2011
- Page last updated: April 14, 2011
- Page last reviewed: April 14, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)